Odyssey Therapeutics (ODTX) Stock Overview
A clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ODTX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Odyssey Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.50 |
| 52 Week High | US$20.30 |
| 52 Week Low | US$15.35 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 6.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| ODTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.7% | 1.2% | 1.0% |
| 1Y | n/a | 34.9% | 28.7% |
Return vs Industry: Insufficient data to determine how ODTX performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how ODTX performed against the US Market.
Price Volatility
| ODTX volatility | |
|---|---|
| ODTX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ODTX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine ODTX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 100 | Gary Glick | odysseytx.com |
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor–associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Odyssey Therapeutics, Inc. Fundamentals Summary
| ODTX fundamental statistics | |
|---|---|
| Market cap | US$836.87m |
| Earnings (TTM) | -US$148.65m |
| Revenue (TTM) | US$2.98m |
Is ODTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ODTX income statement (TTM) | |
|---|---|
| Revenue | US$2.98m |
| Cost of Revenue | US$121.18m |
| Gross Profit | -US$118.20m |
| Other Expenses | US$30.45m |
| Earnings | -US$148.65m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.15 |
| Gross Margin | -3,971.77% |
| Net Profit Margin | -4,994.86% |
| Debt/Equity Ratio | 0% |
How did ODTX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/22 05:35 |
| End of Day Share Price | 2026/05/22 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Odyssey Therapeutics, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.